Weihong Tang1, Mary Rachel Stimson2, Saonli Basu3, Susan R Heckbert4, Mary Cushman5, James S Pankow1, Aaron R Folsom1, Nathan Pankratz2. 1. Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 2. Department of Laboratory Medicine and Pathology, School of Medicine, University of Minnesota, Minneapolis, MN, USA. 3. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 4. Department of Epidemiology, University of Washington, Seattle, WA, USA. 5. Department of Pathology, University of Vermont, Burlington, VT, USA.
Abstract
BACKGROUND: Rare coding mutations underlying deficiencies of antithrombin and proteins C and S contribute to familial venous thromboembolism (VTE). It is uncertain whether rare variants play a role in the etiology of VTE in the general population. OBJECTIVES: We conducted a deep whole-exome sequencing (WES) study to investigate the associations between rare coding variants and the risk of VTE in two population-based prospective cohorts. PATIENTS/ METHODS: Whole-exome sequencing was performed in the Longitudinal Investigation of Thromboembolism Etiology (LITE), which combines the Atherosclerosis Risk in Communities (ARIC) study (316 incident VTE events among 3159 African Americans [AAs] and 458 incident VTEs among 7772 European Americans [EAs]) and the Cardiovascular Healthy Study (CHS; 60 incident VTEs among 1751 EAs). We performed gene-based tests of rare variants (allele frequency < 1%, exome-wide significance P < 1.47 × 10-6 ) separately in each study and ancestry group, and meta-analyzed the results for the EAs in ARIC and CHS. RESULTS: In the meta-analysis of EAs, we identified one gene, PROC, in which the burden of rare, coding variants was significantly associated with increased risk of VTE (HR = 5.42 [3.11, 9.42] for carriers versus non-carriers, P = 2.27 × 10-9 ). In ARIC EAs, carriers of the PROC rare variants had on average 0.75 standard deviation (SD) lower concentrations of plasma protein C and 0.28 SD higher D-dimer (P < .05) than non-carriers. Adjustment for low protein C status did not eliminate the association of PROC burden with VTE. In AAs, rare coding PROC variants were not associated with VTE. CONCLUSIONS: Rare coding variants in PROC contribute to increased VTE risk in EAs in this general population sample.
BACKGROUND: Rare coding mutations underlying deficiencies of antithrombin and proteins C and S contribute to familial venous thromboembolism (VTE). It is uncertain whether rare variants play a role in the etiology of VTE in the general population. OBJECTIVES: We conducted a deep whole-exome sequencing (WES) study to investigate the associations between rare coding variants and the risk of VTE in two population-based prospective cohorts. PATIENTS/ METHODS: Whole-exome sequencing was performed in the Longitudinal Investigation of Thromboembolism Etiology (LITE), which combines the Atherosclerosis Risk in Communities (ARIC) study (316 incident VTE events among 3159 African Americans [AAs] and 458 incident VTEs among 7772 European Americans [EAs]) and the Cardiovascular Healthy Study (CHS; 60 incident VTEs among 1751 EAs). We performed gene-based tests of rare variants (allele frequency < 1%, exome-wide significance P < 1.47 × 10-6 ) separately in each study and ancestry group, and meta-analyzed the results for the EAs in ARIC and CHS. RESULTS: In the meta-analysis of EAs, we identified one gene, PROC, in which the burden of rare, coding variants was significantly associated with increased risk of VTE (HR = 5.42 [3.11, 9.42] for carriers versus non-carriers, P = 2.27 × 10-9 ). In ARIC EAs, carriers of the PROC rare variants had on average 0.75 standard deviation (SD) lower concentrations of plasma protein C and 0.28 SD higher D-dimer (P < .05) than non-carriers. Adjustment for low protein C status did not eliminate the association of PROC burden with VTE. In AAs, rare coding PROC variants were not associated with VTE. CONCLUSIONS: Rare coding variants in PROC contribute to increased VTE risk in EAs in this general population sample.
Authors: David A Hinds; Alfonso Buil; Daniel Ziemek; Angel Martinez-Perez; Rainer Malik; Lasse Folkersen; Marine Germain; Anders Mälarstig; Andrew Brown; Jose Manuel Soria; Martin Dichgans; Nan Bing; Anders Franco-Cereceda; Juan Carlos Souto; Emmanouil T Dermitzakis; Anders Hamsten; Bradford B Worrall; Joyce Y Tung; Maria Sabater-Lleal Journal: Hum Mol Genet Date: 2016-02-09 Impact factor: 6.150
Authors: Valgerdur Steinthorsdottir; Gudmar Thorleifsson; Patrick Sulem; Hannes Helgason; Niels Grarup; Asgeir Sigurdsson; Hafdis T Helgadottir; Hrefna Johannsdottir; Olafur T Magnusson; Sigurjon A Gudjonsson; Johanne M Justesen; Marie N Harder; Marit E Jørgensen; Cramer Christensen; Ivan Brandslund; Annelli Sandbæk; Torsten Lauritzen; Henrik Vestergaard; Allan Linneberg; Torben Jørgensen; Torben Hansen; Maryam S Daneshpour; Mohammad-Sadegh Fallah; Astradur B Hreidarsson; Gunnar Sigurdsson; Fereidoun Azizi; Rafn Benediktsson; Gisli Masson; Agnar Helgason; Augustine Kong; Daniel F Gudbjartsson; Oluf Pedersen; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2014-01-26 Impact factor: 38.330
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Wei Zhou; Jonas B Nielsen; Lars G Fritsche; Rounak Dey; Maiken E Gabrielsen; Brooke N Wolford; Jonathon LeFaive; Peter VandeHaar; Sarah A Gagliano; Aliya Gifford; Lisa A Bastarache; Wei-Qi Wei; Joshua C Denny; Maoxuan Lin; Kristian Hveem; Hyun Min Kang; Goncalo R Abecasis; Cristen J Willer; Seunggeun Lee Journal: Nat Genet Date: 2018-08-13 Impact factor: 38.330
Authors: Nathan Pankratz; Peng Wei; Jennifer A Brody; Ming-Huei Chen; Paul S de Vries; Jennifer E Huffman; Mary Rachel Stimson; Paul L Auer; Eric Boerwinkle; Mary Cushman; Moniek P M de Maat; Aaron R Folsom; Oscar H Franco; Richard A Gibbs; Kelly K Haagenson; Albert Hofman; Jill M Johnsen; Christie L Kovar; Robert Kraaij; Barbara McKnight; Ginger A Metcalf; Donna Muzny; Bruce M Psaty; Weihong Tang; André G Uitterlinden; Jeroen G J van Rooij; Abbas Dehghan; Christopher J O'Donnell; Alex P Reiner; Alanna C Morrison; Nicholas L Smith Journal: Hum Mol Genet Date: 2022-09-10 Impact factor: 5.121